KR100311199B1 - Composition having antimicrobial activity for propionibacterium acnes and inhibition activity for 5alpha-reductase - Google Patents

Composition having antimicrobial activity for propionibacterium acnes and inhibition activity for 5alpha-reductase Download PDF

Info

Publication number
KR100311199B1
KR100311199B1 KR1019970031533A KR19970031533A KR100311199B1 KR 100311199 B1 KR100311199 B1 KR 100311199B1 KR 1019970031533 A KR1019970031533 A KR 1019970031533A KR 19970031533 A KR19970031533 A KR 19970031533A KR 100311199 B1 KR100311199 B1 KR 100311199B1
Authority
KR
South Korea
Prior art keywords
activity
reductase
composition
alpha
acnes
Prior art date
Application number
KR1019970031533A
Other languages
Korean (ko)
Other versions
KR980008238A (en
Inventor
최승만
최영호
김창덕
Original Assignee
성재갑
주식회사 엘지씨아이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 엘지씨아이 filed Critical 성재갑
Publication of KR980008238A publication Critical patent/KR980008238A/en
Application granted granted Critical
Publication of KR100311199B1 publication Critical patent/KR100311199B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489Sophora, e.g. necklacepod or mamani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/35Extraction with lipophilic solvents, e.g. Hexane or petrol ether

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE: A composition having an antimicrobial activity for Propionibacterium acnes and an inhibition activity for 5alpha-reductase is provided, which composition has improved an antimicrobial activity for Propionibacterium acnes and treating and preventing activities for pimples. CONSTITUTION: The composition having an antimicrobial activity for Propionibacterium acnes and an inhibition activity for 5alpha-reductase comprises 0.005 to 10 wt.% of dried powder of Sophora Flavescens extract, in which the dried powder of Sophora Flavescens extract contains 0.05 to 12.9 wt.% of alkaloids as active ingredients for inhibiting the activity of 5alpha-reductase; the Sophora Flavescens extract is produced by dipping Sophora Flavescens in a solvent of at least one selected from purified water, methanol, ethanol, propanol, butanol, glycerol, propyleneglycol, 1,3-butyleneglycol, methylacetate, ethylacetate, benzene, hexane, diethylether and dichloromethane, and by evaporating or freeze-drying the Sophora Flavescens solution.

Description

5α-리덕타아제의 활성 억제작용과 프로피오니박테리움아크네스에 항균작용을 갖는 조성물Composition having inhibitory activity of 5α-reductase and antimicrobial activity on propionibacterium acnes

본발명은 5α-리덕타아제(5α-reductase)의 활성억제작용과 프로피오니박테리움아크네스에 항균작용을 갖는 조성물에 관한 것이다. 더욱 구체적으로, 본 발명은 피지의 과잉 생성을 근본적으로 억제하는 작용이 뛰어난 고삼(Sophora flavescens) 추출물을 함유한 조성물에 관한 것이다.The present invention relates to a composition having an inhibitory activity of 5α-reductase and an antimicrobial action on propionibacterium acnes. More specifically, the present invention relates to a composition containing the extract of Sophora flavescens, which is excellent in fundamentally inhibiting the excessive production of sebum.

남성형 탈모, 여드름, 지루성 피부염 등은 남성호르몬의존성(androgen-dependent disorders) 만성 피부질환(Van Luu-The 외 5인; Characterization, Expression, and Immunohistochemical Localization of 5α-Reductase in Humna Skin, J. Invest. Dermatol, 102, 221-226, 1994)이다. 그 중 중년의 남성에게 심각한 정신적 상처를 줄 수 있는 남성형 탈모는 남성 호르몬의 양에 직접적으로 관계되며, 최근 남성호르몬 활성억제를 통한 탈모의 예방 및 치료를 위한 많은 연구가 보고되고 있다. 또한 만성 피부질환중 여드름과 지루성 피부염은 피지관련질환(sebum-related disorders)로 남성호르몬에 의해 생성된 과잉의 피지에 의해서 발병하는 질환이며 근본적인 치료를 위해서는 남성호르몬의 활성억제를 통하여 피지의 과잉 생성을 억제하여야 한다.Androgenetic alopecia, acne and seborrheic dermatitis include chronic skin diseases (androgen-dependent disorders) and chronic skin diseases (Van Luu-The et al. 5; Characterization, Expression, and Immunohistochemical Localization of 5α-Reductase in Humna Skin, J. Invest.Dermatol) , 102, 221-226, 1994). Male hair loss, which can cause serious mental injury among middle-aged men, is directly related to the amount of testosterone. Recently, many studies have been reported for the prevention and treatment of hair loss through the inhibition of male hormone activity. In addition, acne and seborrheic dermatitis in chronic skin diseases are sebum-related disorders caused by excess sebum produced by male hormones. For the fundamental treatment, sebum overproduction is inhibited through the inhibition of male hormone activity. Should be suppressed.

남성호르몬의 작용을 피지생성 기전과 연관하여 간략히 설명하면 다음과 같다. 남성 호르몬 중의 하나인 테스토스테론(testosterone)은 5알파-리덕타아제에 의하여 활성 남성호르몬인 다이하이드로테스토스테론(dihydrotestosterone)으로 전환되고, 이 호르몬의 비정상적인 과잉작용은 남성형 탈모를 야기하는 물질로 작용함과 동시에 피지세포(sebocyte)에서 피지(sebum)를 과잉생성하는 주 원인 물질로 작용한다. 상기의 기전에 의하여 피지가 비정상적으로 과잉 생성 또는 분비되면 피지관련 질환(여드름, 지루성 피부염)을 일으키게 된다. 결과적으로 남성형 탈모, 여드름 및 지루성피부염 등은 5알파-리덕타아제의 작용에 의한 다이하이드로테스토스테론의 과잉생성 때문이며 5알파-리덕타아제의 활성을 억제한다면 상기의 질환을 근본적이고 효과적으로 예방 및 치료를 할 수 있을 것이다.Briefly explaining the action of male hormones in connection with the sebum production mechanism is as follows. Testosterone, one of the testosterones, is converted to dihydrotestosterone, an active male hormone, by 5 alpha-reductase, and the abnormal overaction of this hormone acts as a substance causing male hair loss. It acts as a major causative agent for the overproduction of sebum in sebocytes. Abnormally excessive production or secretion of sebum by the above mechanism will cause sebum-related diseases (acne, seborrheic dermatitis). As a result, masculine alopecia, acne and seborrheic dermatitis are due to the overproduction of dihydrotestosterone by the action of 5 alpha-reductase, and if the activity of 5 alpha-reductase is inhibited, the disease can be prevented and treated fundamentally and effectively. You can do it.

상기의 질환중 여드름의 경우 과잉으로 생성된 피지이외에 중요한 하나의 인자가 그 질환의 악화에 중요하게 작용하는데, 구체적으로 설명하면 다음과 같다. 상기의 기전으로 생성된 피지가 모공의 과각화로 인하여 모공 밖으로 배출되지 못하면 1차적인 미세면포(micro-comedones)가 형성되며 모공의 피지 내에 존재하는 혐기성 피부상재균인 프로피오니박테리움아크네스(이하, 피. 아크네스)의 작용에 의하여 만성 염증성 질환인 구진(papule), 농포(pustule), 낭종(cyst), 결절(nodule)로 발전하게 되며 심하게 되면 반흔(scar)을 일으키게 된다. 결과적으로 여드름의 경우는 피지의 과잉생성, 모공의 과각화 및 피. 아크네스의 작용 등 여러 복합적인 인자로 인하여 발병하는 질환으로 설명된다.In the case of acne of the above diseases, one factor important other than excessively produced sebum plays an important role in exacerbation of the disease. If sebum produced by the above mechanism is not discharged out of the pores due to the hyperkeratosis of the pores, primary micro-comedones are formed and propionibacterium acnes (hereinafter referred to as anaerobic superficial bacteria) present in the sebum of the pores. , P. acnes) is a chronic inflammatory disease of papule (papule), pustules (pustule), cysts (cyst), nodules (nodule) develops and, if severe, scars (scar). As a result, in the case of acne, overproduction of sebum, hyperkeratosis of pores and blood. It is described as a disease caused by several complex factors such as the action of Acnes.

이러한 여드름, 남성형 탈모 및 지루성 피부염 등 남성호르몬 관련질환을 예방 또는 치료하기 위하여 현재까지 5알파-리덕타아제의 활성을 억제하려는 많은 연구가 보고되고 있으며(Yasuro Sugimoto 외 3인; Cations Inhibit Specifically Type I 5α-Reductase Found in Human Skin, J. Invest. Dermatol, 104, 775-778, 1995), 몇몇 물질들이 발견되고 있으나, 그 효과나 실용성이 적고 그의 사용에 상당한 주의가 필요하다. 또한 여드름의 경우 피, 아크네스에 대한 항균물질로 테트라사이클린 등의 항생물질을 사용할 경우 내성 균의 출현 또는 광과민 작용 등의 부작용을 일으킬 가능성이 크다고 알려져 있다.Many studies have been reported to inhibit the activity of 5-alpha-reductase to prevent or treat male hormone-related diseases such as acne, androgenetic alopecia and seborrheic dermatitis (Yasuro Sugimoto et al. 3; Cations Inhibit Specific Type I). 5α-Reductase Found in Human Skin, J. Invest.Dermatol, 104, 775-778, 1995), although several substances have been found, their effectiveness and practicality are small and considerable care is required for their use. In addition, in the case of acne, it is known that the use of antibiotics such as tetracycline as an antimicrobial agent for blood and acnes is likely to cause side effects such as the appearance of resistant bacteria or photosensitivity.

본 발명자는 이러한 문제점을 고려하여 여드름, 남성형탈모 및 지루성 피부염 등 남성호르몬 관련질환의 근본적 원인인 활성 남성호르몬의 생성을 억제하기 위하여, 그 생성에 직접적으로 관여하는 5알파-리덕타아제의 활성을 강력히 억제하는 동시에 여드름 악화의 주 원인균으로 알려진 피. 아크네스에 대해 뛰어난 항균작용을 갖고 있고 장시간 사용해도 안전성이 높은 물질을 개발하기 위하여 각종 천연물을 대상으로 체계적인 연구를 수행한 결과, 세안제, 비누 및 크림조성물에 고삼추출물을 함유 시키면 낮은 농도에서 5알파-리덕타아제의 활성을 강력히 억제하며 동시에 피 아크네스에 강력한 항균효과가 있다는 놀라운 사실을 밝혀냈다.In view of these problems, the present inventors consider the activity of 5 alpha-reductase that is directly involved in the production of active male hormones, which are the main causes of male hormone-related diseases such as acne, male alopecia and seborrheic dermatitis. Blood is known to be a potent inhibitor of acne. As a result of systematic research on various natural products to develop a material having excellent antibacterial activity against Aknes and high safety even for a long time use, high alpha extract in facial cleanser, soap and cream composition is 5 alpha at low concentration. It has been found to be a remarkable fact that it strongly inhibits the activity of reductase and at the same time has a strong antibacterial effect on piacnes.

본 발명은 고삼추출물의 건주분말을 0.005 내지 10 중량% 함유함을 특징으로 하는 피지생성억제작용을 갖는 액상, 크림상, 페이스트상 또는 고체상 조성물에 관한 것이다.The present invention relates to a liquid, cream, paste or solid composition having a sebum production inhibitory action, characterized by containing 0.005 to 10% by weight of dry powder of high ginseng extract.

본 발명에서 사용된 고삼의 일반적인 성상, 응용 및 확인 시험법은 다음과 같다. 학명은 소포라 플라베센스(Sophora flavescenes) 또는 소포라 안구스티폴리아(Sophora angustifolia)이며, 생약명은 소포라에 라딕스(Sophorae radix)로 뿌리를 생약으로 사용한다. 고삼의 성상은 원주형 또는 원추형의 뿌리로서 길이 5∼20cm, 직경 2∼3cm이고 외면은 암갈색∼황갈색이고 세로 주름이 뚜렷하며, 주피를 벗긴 것은 황백색이고 섬유성을 나타낸다. 또한, 특유한 구토성의 냄새가 나고 맛은 쓰며 잔류성(殘留性)이 있다. 가장 대표적인 주성분인 알칼로이드류로서는 마트린(matrin), 옥시마트린(oxymatrine), 소포라놀(sophoranol) 등이 있으며, 플라보노이드류(flavonoids)로는 큐라리딘(kuraridin), 이소안하이드로이카리틴(isoanhydroicaritin) 등이 있다. 또한 잎은 루테오닌-7-글루코스(luteolin-7-glucose)를 함유하고 있으며, 종자는 사이티신(cytisine) 등을 함유하고 있다.General properties, applications and confirmation of the ginseng used in the present invention is as follows. The scientific name is Sophora flavescenes or Sophora angustifolia, and the herbal name is Sophorae radix, which uses the root as a herbal medicine. The ginseng has the shape of columnar or conical root, 5 ~ 20cm long, 2 ~ 3cm in diameter, dark brown to yellow brown on the outer surface, clear vertical wrinkles, yellowish white, and peeled off skin. In addition, it has a unique nausea, smells bitter, and is persistent. Alkaloids, which are the most representative ingredients, include matrin, oxymatrine, and sophoranol. Flavonoids include curaridin and isohydroicaritin. have. The leaves also contain luteolin-7-glucose, and the seeds contain cytisine and the like.

고삼의 용도는 고미건위제(苦味建胃劑), 말초 혈관수축제, 해열진통제 및 피부기생충구제제 등으로 사용되며, 독성은 0.4g/kg 이므로 대량 복용은 피한다(참조: 한대석 외 ; 생약학, 동명사, 194-196, 1994). 확인 시험법으로는 고삼 추출물 0.5g에 물 10㎖을 넣고 끓인 다음 여과해서 여액 2㎖에 마이어시약(mayer reagent) 2∼3 방울 떨어뜨리면 황색 침전이 생성된다(참조 : 마트린 등의 알칼로이드 류 확인 시험, 대한약전 VI).Ginseng is used as a high-density chemical agent, peripheral vasoconstrictor, antipyretic analgesic, and parasitic parasite. Toxicity is 0.4g / kg, so avoid large doses (Ref. Han Dae-seok; 194-196, 1994). As a confirmation test, 0.5 g of red ginseng extract is added with 10 ml of water, boiled, filtered, and 2 ml of mayer reagent is dropped into 2 ml of the filtrate. A yellow precipitate is formed (refer to alkaloids such as martrin). Test, Korean Pharmacopoeia VI).

<고삼 추출물의 제조><Production of Ginseng Extract>

본 발명에 사용된 고삼의 추출 방법을 설명하면 다음과 같다. 먼저 고삼 뿌리를 세정하고 분말화하여 약 10배량의 추출 용매로 상온에서 5일간 냉침한 후 추출원액을 여과, 농축 및 동결건조 등의 방법을 통하여 고삼 추출물의 건조분말을 얻었다. 이때 사용한 추출 용매로는 정제수, 메탄올, 에탄올, 프로판을, 부탄올, 글리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜, 메틸아세테이트, 에틸아세테이트, 벤젠, 핵산, 디에틸에테르 및 디클로로메탄 중에서 선택된 하나 또는 두종류 이상의 혼합용매를 이용하여 추출에 사용하는 것이 바람직하다.Referring to the extraction method of ginseng used in the present invention is as follows. First, the ginseng roots were washed and powdered, and then cooled for 5 days at room temperature with an extract solvent of about 10 times, and then the extract powder was dried, and the dried powder of the ginseng extract was obtained by filtration, concentration, and freeze drying. The extraction solvent used at this time is purified water, methanol, ethanol, propane, butanol, glycerol, propylene glycol, 1,3-butylene glycol, methyl acetate, ethyl acetate, benzene, nucleic acid, diethyl ether and dichloromethane or It is preferable to use two or more types of mixed solvents for extraction.

<고삼 추출물의 5알파-리덕타아제 활성 억제력 평가실험><Evaluation of 5 Alpha-reductase Activity Inhibitory Activity of Ginseng Extract>

5알파-리덕타아제 활성억제 실험에 사용된 5알파-리덕타아제는 쥐의 간(adult, Sprague-Dawley, male rat(8-10 weeks old), liver)에서 얻었으며 단백질 정량을 통하여 일정량의 단백 현탁액(protein suspension)을 준비하였다. 또한 일반적인 방법으로 효소반응용액(enzyme reaction solution)을 준비 하였다. 5알파-리덕타아제의 반응기질(substrate)로서는 방사선표지(radio labeled)된 테스토스테론(3H testosterone)을 사용하며, 효소반응용액 : 단백질현탁액 : 고삼추출물 = 70 : 20 : 10의 비율로 2분간 항온조(incubator)에서 반응시킨 후 반응 용매를 중발시키고 남은 물질을 전개 용매에 녹여 박층크로마토그램(TLC)에 전개하고, 전개된 테스토스테론의 양과 다이하이드로테스토스테론 양을 덴시토미터(densitometer)를 이용하여 정량 분석하여 5알파-리덕타아제에 의한 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(conversion rate)을 측정하고, 그 결과를 대조군(고삼추출물을 첨가하지 않았을때의 전환율)과 비교하여 5알파-리덕타아제 억제율을 평가하였다. 억제율 평가 계산방법은 아래와 같다.5 alpha-reductase activity inhibitory 5 alpha-reductase was used in the liver of rats (adult, Sprague-Dawley, male rat (8-10 weeks old), liver), A protein suspension was prepared. In addition, an enzyme reaction solution was prepared in a general manner. Radiolabeled testosterone ( 3 H testosterone) is used as a substrate of 5 alpha-reductase, and enzyme reaction solution: protein suspension: high ginseng extract = 70: 20: 10 for 2 minutes. After reacting in an incubator, the reaction solvent is decanted and the remaining material is dissolved in a developing solvent and developed on a thin layer chromatogram (TLC), and the amount of testosterone and dihydrotestosterone is quantified using a densitometer. Analysis was performed to determine the conversion rate of testosterone to dihydrotestosterone by 5 alpha-reductase, and to compare the results with the control (conversion rate without the addition of high ginseng extract) to 5 alpha-reductase. Inhibition rate was evaluated. The calculation method of inhibition rate evaluation is as follows.

억제율(%) = [(A-B)/시 x 100% Inhibition = [(A-B) / hour x 100

A = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 미첨가시)A = conversion of testosterone to dihydrotestosterone (without extract)

B = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 첨가시)B = conversion of testosterone to dihydrotestosterone (extract added)

Figure kpo00001
Figure kpo00001

<고삼 추출물의 피. 아크네스에 대한 항균력 평가실험><Blood of Gosam extract. Antibacterial Activity Test for Acnes>

상기의 방법에 의하여 얻어진 고삼추출물의 항균력 실험은 액체 배지에서 배양시킨 피. 아크네스에 일정 농도의 고삼 추출물을 가하여 혐기성 배양조에서 배양한 후 피. 아크네스의 발육을 억제하는 최소억제농도(MIC)를 구하였으며, 그 결과 각 추출 용매에 의한 고삼 추출물의 피. 아크네스에 대한 최소억제농도(MIC)범위는 10∼100 ppm으로 평가되었다.The antimicrobial activity of the high ginseng extract obtained by the above method was cultured in liquid medium. After adding a certain concentration of ginseng extract to Aknes, incubated in an anaerobic culture tank. The minimum inhibitory concentration (MIC) was determined to inhibit the growth of Acnes. The minimum inhibitory concentration (MIC) range for Acnes ranged from 10 to 100 ppm.

<유효성분의 분리 및 동정><Isolation and Identification of Active Ingredients>

고삼 추출물 중의 5알파-리덕타아제를 강력히 억제하는 유효성분 및 우수한 항균성을 나타내는 유효성분을 탐색하기 위하여 상기의 방법에 의하여 얻은 일차 용매추출물을 극성인 물층과 물보다 비극성인 용매층(예를들면 디에틸에테르, 디클로로메탄 및 헥산 등)에 용매 분획하여 각각 용매층에 이행된 유효성분의 5알파-리덕타아제 억제력을 평가한 결과, 비극성 용매층에 우수한 억제력(0.001%에서 100%의 억제율)를 나타내는 유효성분이 이행되어 있음을 확인하였으며, 피. 아크네스에 대한 최소 억제농도를 평가한 결과, 물층(MIC : 약 200ppm)보다 비극성 용매층(MIC :1∼10 ppm)에서 강력한 항균작용이 있음을 확인하여, 두 실험 모두에서 유효성분들이 비극성 용매층으로 이행하였음을 확인할 수 있었다.In order to search for an active ingredient that strongly inhibits 5 alpha-reductase and an active ingredient exhibiting excellent antimicrobial activity in the extract, the primary solvent extract obtained by the above method is a polar water layer and a nonpolar solvent layer (eg Solvent fractionation in diethyl ether, dichloromethane, hexane and the like) evaluated the 5 alpha-reductase inhibitory power of the active ingredient transferred to the solvent layer, respectively. As a result, the superior inhibitory power (0.001% to 100% inhibition rate) in the nonpolar solvent layer was evaluated. It was confirmed that the active ingredient indicating was implemented, p. As a result of evaluating the minimum inhibitory concentration for Acnes, it was confirmed that the antimicrobial activity was stronger in the nonpolar solvent layer (MIC: 1 to 10 ppm) than the water layer (MIC: about 200 ppm). It was confirmed that the transition to the floor.

본 연구를 더욱 진행시켜 우수한 5알파-리덕타아제 억제 및 항균성을 나타내는 유효성분의 분리(isolation 또는 separation) 및 동정(identification)을 위하여 상기의 방법에 의하여 비극성 용매층으로 이행된 추출물을 이상-용매시스템(two-phase solvents system)으로 전개시켜 각각의 극성도에 따라 유효성분을 분리 및 분취하는 칼럼크로마트그래피를 이용하였으며, 시간에 따라 용출된 각각의 유효성분을 박층크로마트그래피(TLC)를 이용하여 같은 성분이 포함된 분취용액올 합하여 5알파-리덕타아제 억제실험 및 항균성 실험을 한 후 우수한 억제성 및 항균성을 나타내는 유효성분을 동정하였으며, 그 방법으로는 표품을 통한 확인 및 각종 분석장비를 이용한 동정을 실시하여 유효성분들을 최종확인하였다.The present study further proceeds to an over-solvent of the extract transferred to the non-polar solvent layer by the above method for isolation or separation and identification of the active ingredient exhibiting excellent 5-alpha-reductase inhibition and antimicrobial activity. Column chromatography was used to develop two-phase solvents system to separate and fractionate the active ingredients according to the polarity of each layer, and thin layer chromatography (TLC) Using 5 alpha-reductase inhibitory test and antimicrobial test by combining preparative solutions containing the same components, we identified the active ingredient showing excellent inhibitory and antimicrobial properties. The identification was performed to confirm the effective ingredients.

상기의 방법으로 유효성분의 동정 실험을 실시한 결과, 5알파-리덕타아제를 강력히 억제하는 유효성분군은 마트린 등의 알칼로이드류(1x10-5%에서 100%억제)인 것으로 밝혀졌다. 또한 피. 아크네스에 대한 강력한 항균작용을 나타낸는 두 종류의 성분군을 분리하였으며, 하나는 마트린, 알로마트린, 옥시마트린, 소포라놀 등의 알칼로이드류이고, 다른 하나는 이소안하이드로이카리틴, 큐라리논, 큐라리딘 및 소포라플바논 G 등의 플라보노이드류인 것을 확인하였다. 본 발명의 조성물에서 고삼추출물의 건조분말중에 알칼로이드류는 0.05 내지 12.9 중량% 함유하고, 플라보노이드류는 0.005 내지 11.3 중량% 함유하는 것이 바람직하다. 이때 알칼로이드류(MIC : 약 1 ppm)에 비하여 플라보노이드류(MIC:0.1∼1 ppm)가 더욱 우수한 항균력을 나타내는 것을 확인하였다.As a result of the identification experiment of the active ingredient by the above method, it was found that the active ingredient group that strongly inhibits 5 alpha-reductase is alkaloids such as martrin (1x10 -5 % to 100% inhibition). Also blood. Two types of constituents showing strong antimicrobial activity against Acnes were isolated. One is alkaloids such as matrin, allomatrine, oxymatrine, and sophoranol, and the other isoan hydrocaritine, curarinone, cura It was confirmed that they were flavonoids, such as a ridine and a sophoralfannon G. Alkaloids in the dry powder of high ginseng extract in the composition of the present invention is preferably contained 0.05 to 12.9% by weight, flavonoids preferably contain 0.005 to 11.3% by weight. At this time, it was confirmed that the flavonoids (MIC: 0.1-1 ppm) showed more excellent antimicrobial activity than the alkaloids (MIC: about 1 ppm).

5알파-리덕타아제 억제 실험 및 피. 아크네스에 대한 항균력 평가실험에 사용된 각종 추출용매에 의하여 추출한 고삼 추출물을 고속액체크로마트그래피(HPLC)를 이용하여 추출물중의 마트린, 알로마트린, 옥시마크린, 소포라놀등 알칼로이드류의 함량 평가실험을 한 결과, 추출용매의 종류에 따라 약간의 차이는 있으나 용매 추출물의 건조분말 중 알칼로이드류의 함량은 0.05∼12.9 중량% 범위 내에 있는 것을 확인하였으며, 플라보노이드류의 함량은 0.005∼11.3 중량% 범위내에 있었다.5 alpha-reductase inhibition experiments and blood. The content of alkaloids such as matrin, allomatrine, oxymacrine, and sophoranol in the extract using high-performance liquid chromatography (HPLC) from the extract of Ginseng extracted by various extraction solvents used in the evaluation of antibacterial activity against Acnes As a result of the evaluation experiment, it was confirmed that the alkaloids in the dry powder of the solvent extract was in the range of 0.05 to 12.9% by weight, but the flavonoids were in the range of 0.005 to 11.3% by weight, depending on the type of the extraction solvent. It was in range.

상기의 방법에 의하여 유효성분을 확인한 본 발명자는 추출물을 함유시킨 세안제, 비누, 크림 등의 조성물을 제조하여 5알파-리덕타아제 활성억제력과 피. 아크네스에 대한 살균력(세안제, 비누, 크림)을 평가하였으며, 고삼의피지생성억제작용 및 피. 아크네스에 대한 살균효과를 임상으로 확인하고자 피지의 과잉분비 요인 및 피. 아크네스 요인의 대표적 복합관련 질환인 여드름의 치료효과를 평가하기 위하여 임상실험(세안제)을 한 결과 고삼 추출물을 함유한 조성물이 피부발적 등의 부작용을 나타내지 않으면서 여드름 치료효과도 우수한 것으로 평가되었다.The present inventors confirmed the active ingredient by the above method to prepare a composition such as a cleanser, soap, cream containing the extract 5 alpha-reductase activity inhibitory power and blood. The bactericidal power (cleanser, soap, cream) against acnes was evaluated. To determine the bactericidal effect on Acnes clinically. In order to evaluate the treatment effect of acne, which is a representative complex related disease of Acnes factor, a clinical experiment (washing agent) showed that the composition containing Ginseng extract was excellent in treating acne without showing side effects such as skin redness.

본 발명은 상기의 방법에 의하여 얻은 고삼 추출물올 함유하여 5알파-리덕타아제의 활성을 강력하게 억제하고 피. 아크네스에 뛰어난 항균작용을 갖는 조성물에 관한 것으로, 세안제, 비누 및 크림을 포함한다. 본 발명의 각각의 조성물은 과지방을 함유하지 않은 일반적인 각각 제품의 베이스를 기본으로 하며, 각각의 조성물 전체에 대하여 고삼 추출물의 건조분말을 0.005∼10 중량% 함유하는 것이 바람직하다.The present invention contains a ginseng extractol obtained by the above method to strongly inhibit the activity of 5 alpha-reductase and blood. The present invention relates to a composition having excellent antibacterial activity to Acnes, and includes face washes, soaps and creams. Each of the compositions of the present invention is based on the base of each of the general products without containing excess fat, and preferably contains 0.005 to 10% by weight of dry powder of ginseng extract with respect to the entire composition.

본 발명에서 세안제 및 비누는 세안제 및 비누 베이스에 고삼 추출물을 함유시키며, 여드름, 남성형 탈모 및 지루성 피부염 등의 질환에 임상효과를 상승시키기 위하여 알파하이드록시 산(α-hydroxy acid), 베타하이드록시 산(β-hydroxy acid) 또는 피부 각질제거제(kelatolytic 또는 exfoliating agents) 등을 첨가하여 사용할 수 있다. 또한 향료, 색소, 살균제, 산화방지제, 방부제, 보습제 등을 사용할 수 있으며, 점증제, 무기염류, 합성고분자 물질 등을 물성개선을 위하여 사용할 수 있다. 또한 본 발명에서 크림은 일반적인 수중유형(O/W)의 베이스에 고삼 추출물을 함유시키고, 향료, 색소, 산화방지제, 방부제 등을 사용할 수 있으며, 물성개선을 위하여 합성 또는 천연 소재를 사용할 수 있다.In the present invention, the face wash and soap contains a ginseng extract in the face wash and soap base, alpha-hydroxy acid, beta-hydroxy acid in order to increase the clinical effect on diseases such as acne, male hair loss and seborrheic dermatitis (β-hydroxy acid) or kelatolytic or exfoliating agents can be used. In addition, fragrances, pigments, fungicides, antioxidants, preservatives, moisturizers and the like can be used, and thickeners, inorganic salts, synthetic polymer materials and the like can be used for physical property improvement. In the present invention, the cream contains a ginseng extract in the base of the general oil-in-water type (O / W), and may use fragrances, pigments, antioxidants, preservatives, etc., and synthetic or natural materials may be used for physical property improvement.

본 발명의 세안제, 비누 및 크림은 통상적인 제조방법으로 용이하게 제조할 수 있다. 본 발명에 따른 5알파-리덕타아제의 활성억제 작용과 피. 아크네스에 항균 작용을 갖는 조성물의 성상은 서로 다른 제형 즉 액상, 크림상, 페이스트상 또는 고체상 등의 어떠한 성상에도 적용이 용이하다.The face wash, soap and cream of the present invention can be easily prepared by conventional manufacturing methods. Inhibitory activity and activity of 5 alpha-reductase according to the present invention. The composition of the composition having an antimicrobial action on Acnes is easy to apply to any of the other formulations, such as liquid, cream, paste or solid phase.

이하 본 발명을 실시예 및 비교예에 의거하여 설명하지만, 이들 실시예로 본 발명의 기술적 범위가 한정되는 것은 아니다.Hereinafter, although an Example and a comparative example demonstrate this invention, the technical scope of this invention is not limited to these Examples.

[실시예 1: 고삼 추출물 함유세안제 조성물의 제조 및 효능실험]Example 1: Preparation and efficacy test of ginseng extract-containing cleansing composition

세안제 베이스와 고삼 추출물의 혼합물을 호모믹서기에서 교반, 가열, 탈기, 냉각 등의 과정을 거쳐 조성물질이 균일하게 혼합되도록 실시예 및 비교예의 세안제 조성물을 제조하였다.The face wash composition of Examples and Comparative Examples was prepared such that the mixture of the face wash base and the ginseng extract was uniformly mixed in the homomixer through stirring, heating, degassing, and cooling.

(단위:중량%)(Unit: weight%)

Figure kpo00002
Figure kpo00002

5알파-리덕타아제 활성 억제력 평가실험5-alpha-reductase activity inhibitory evaluation test

상기 실시예 및 비교예에서 제조한 세안제 조성물의 5알파-리덕타아제에 대한 활성억제력을 평가하기 위하여 5%의 실시예 및 비교예 세안제 수용액을 실험액으로 제조하여 상기에 설명한 방법으로 5알파-리덕타아제 활성 억제력을 평가하였다. 억제율 평가 계산 방법은 아래와 같다.In order to evaluate the activity inhibitory activity against the 5 alpha-reductase of the cleanser composition prepared in the above Examples and Comparative Examples, 5% aqueous solution of the Examples and Comparative Examples was prepared as a test solution and 5alpha- Inhibition of reductase activity was evaluated. The inhibition rate calculation method is as follows.

억제율(%) = [(A-B)/A] x 100% Inhibition = [(A-B) / A] x 100

A = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 미첨가시)A = conversion of testosterone to dihydrotestosterone (without extract)

B = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 첨가시)B = conversion of testosterone to dihydrotestosterone (extract added)

5알파-리덕타아제 활성억제력은 80% 이상의 결과가 있어야 효과가 있는 것으로 판단한다.5 alpha-reductase activity inhibitory effect is judged to be effective only when 80% or more result.

상기 5알파-리덕타아제의 활성억제력 실험결과는 하기 표 1-1과 같다.The activity inhibitory test results of the 5 alpha-reductase are shown in Table 1-1.

[표 1-1]Table 1-1

Figure kpo00003
Figure kpo00003

피. 아크네스에 대한 살균력 실험blood. Bactericidal Test on Acnes

상기 실시예 및 비교예에서 제조한 세안제 조성물의 피. 아크네스에 대한 항균력을 평가하기 위하여 패트리디쉬(박테리아 배양용 접시)에 피. 아크네스를 접종한 후 3일간 혐기성 배양조에서 배양하고 피. 아크네스의 집락수(N1)를 측정하였으며, 5%의 실시예 및 비교예 세안제 수용액을 패트리디쉬 상에 떨어뜨려 3일 이상 혐기성 배양조에서 배양시킨 후 집락수(N2)를 측정하였다. 상기에 의하여 구하여진 집락수를 아래의 방법을 이용하여 피. 아크네스에 대한 살균율을 평가하였다.Blood of the face wash composition manufactured in the said Example and a comparative example. To evaluate antimicrobial activity against Acnes, pour into petri dishes (bacterial dish). Incubate in an anaerobic culture tank for 3 days after inoculation with acnes and bleed. The colony number (N 1 ) of Acnes was measured, and the colony number (N 2 ) was measured after incubating in an anaerobic culture vessel for 3 days or more by dropping an aqueous solution of 5% Examples and Comparative Examples on a petri dish. The number of colonies obtained by the above is avoided using the following method. The sterilization rate for Acnes was evaluated.

Figure kpo00004
Figure kpo00004

피, 아크네스의 살균율은 90% 이상의 결과가 있어야 살균 효과가 있는 것으로 판단한다.The bactericidal rate of blood and acnes should be 90% or more to be effective.

상기 피. 아크데스에 대한 살균력 실험결과는 하기표 1-2에 나타내었다.Said blood. The bactericidal test results for the Acdes are shown in Table 1-2 below.

[표 1-2]TABLE 1-2

Figure kpo00005
Figure kpo00005

고삼의 임상효과 평가실험Evaluation of Clinical Effect of Korean Ginseng

상기의 실험에서 확인한 고삼의 5알파-리덕타아제에 대한 뛰어난 활성억제 효과와 피. 아크네스에 대한 강력한 살균작용을 임상에서 확인하고자 그 두가지의 복합작용에 의하여 발생되는 대표적인 질환인 여드름에 대한 임상효과를 실험하였다. 고삼 추출물을 함유한 세안제(실시예 1-3)와 이를 함유하지 않은 세안제(비교예 1-2)를 사용하여 여드름 예방 및 치료에 관한 임상효과를 측정하기 위하여 10대 후반∼20대 후반의 남성(실험군:10명, 대조군:10명)을 피 시험자로 선정한 뒤 1일 3회, 한달간 사용하도록하여 여드름 예방 및 치료효과를 평가하였다.Excellent activity inhibitory effect and blood on 5 alpha-reductase of Ginseng identified in the above experiment. In order to confirm the potent bactericidal action against Acnes in clinical trials, we tested the clinical effect on acne, a representative disease caused by the combination of the two. Men in their late teens to late twenties to determine the clinical effects of acne prevention and treatment using facial cleansers containing Gosam extract (Examples 1-3) and facial cleansers (Comparative Examples 1-2). (Experimental group: 10, control group: 10) was selected as a test subject and used three times a day for one month to evaluate the prevention and treatment of acne.

판정방법은 실험을 시작하기전에 여드름의 상태에 따라 일정한 등급을 매긴후, 육안 관찰에 의한 면포 감소를 확인하는 것이며 판정기준은 다음과 같다.Judging method is to determine the reduction of cotton cloth by visual observation after grading a certain grade according to the condition of acne before starting the experiment.

Figure kpo00006
Figure kpo00006

임상실험 대상자의 여드름에 대한 등급이 3등급 이상의 감소를 나타내면 효과 우수, 1∼2의 감소를 나타내면 효과 중간, 감소가 나타나지 않으면 효과없음, 시험전의 등급보다 시험후의 등급이 높으면 악화되는 것으로 판정한다. 상기 여드름예방 및 치료효과에 대한 실험결과는 하기 표 1-3에 나타내었다.It is judged that if the grade of acne of clinical trial subjects shows a reduction of 3 or more grades, the effect is excellent; if the decrease of 1-2 is shown, the effect is moderate; if the decrease does not appear, there is no effect; Experimental results for the prevention and treatment of acne are shown in Tables 1-3 below.

표 1-3(세안제)Table 1-3 (Cleanser)

Figure kpo00007
Figure kpo00007

상기 세안제의 실험결과를 종합하여보면, 고삼 추출물을 함유한 세아제가 이를 함유하지 않은 것보다 5알파-리덕타아제의 활성을 강력하게 억제하는 것으로 나타났으며, 피. 아크네스에 대한 살균력 또한 탁월한 것으로 나타났고, 임상실험 결과에서도 매우 우수한 여드름 치료효과가 있는 것으로 나타났다. 또한 위의 결과에서 보듯이 고삼 추출물 0.005중량% 미만의 첨가시는 피지생성 억제력 및 피. 아크네스에 대한 살균력이 다소 낮은 것으로 나타났으며, 10 중량% 초과 시는 피지생성억제력은 우수하지만 제조상의 어려움이 있었다. 따라서 본 발명에 사용된 세안제 내의 고삼 추출물의 함량은 0.005∼10 중량% 범위내에서 피지생성 억제력, 피. 아크네스에 대한 살균력 및 작업성이 매우 우수한 것으로 나타났다.In summary, the results of the experiment of the face wash, it was shown that the enzyme containing the ginseng extract inhibits the activity of 5 alpha-reductase strongly than that of the extract, blood. The bactericidal activity against Acnes was also shown to be excellent, and clinical trials showed very good acne treatment. In addition, as shown in the results above, ginseng extract inhibition and sebum production when less than 0.005% by weight. The bactericidal power against Acnes was found to be somewhat low, and when it exceeds 10% by weight, the sebum production inhibitory ability was excellent, but there were manufacturing difficulties. Therefore, the content of ginseng extract in the face wash used in the present invention is within the range of 0.005 to 10% by weight of sebum production inhibitory activity, blood. The bactericidal power and workability for Acnes were found to be very good.

나) 실시예 2 : 고삼 추출물 함유 비누 조성물의 제조 및 효능실험B) Example 2 Preparation and Efficacy Test of Soap Composition Containing Ginseng Extract

비누 베이스와 고삼추출물을 혼합기에 잘 혼합한 후, 비누 제조기계에서 압출, 절단, 형타하여 고형 비누형태의 비누 조성물을 제조하였으며, 상기의 고삼 추출물은 일반 비누뿐만 아니라 통상의 비누 제조방법에 의하여 합성 비누와 복합비누에도 포함하여 제조할 수 있다.After mixing the soap base and the ginseng extract in a mixer well, the soap composition in the form of a solid soap was prepared by extrusion, cutting and molding in a soap manufacturing machine, the extract of the ginseng is synthesized by a conventional soap manufacturing method as well as general soap. It can also be included in soaps and complex soaps.

Figure kpo00008
Figure kpo00008

5알파-리덕타아제 활성 억제력 평가실험5-alpha-reductase activity inhibitory evaluation test

상기 실시예 및 비교예에서 제조한 비누 조성물의 5알파-리덕타아제에 대한 활성 억제력을 평가하기 위하여 5%의 실시예 및 비교예 비누 수용액을 실험액으로 제조하여 상기에 설명한 방법으로 5알파-리덕타아제 활성 억제력을 평가하였다. 억제율 평가 계상방법은 아래와 같다.In order to evaluate the inhibitory activity of 5-alpha-reductase activity of the soap compositions prepared in the above Examples and Comparative Examples, 5% aqueous solution of Examples and Comparative Examples was prepared as a test solution and 5 alpha- Inhibition of reductase activity was evaluated. The method of estimating inhibition rate is as follows.

억제율(%) = [(A-B)/A] x 100% Inhibition = [(A-B) / A] x 100

A = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 미첨가시)A = conversion of testosterone to dihydrotestosterone (without extract)

B = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 첨가시)B = conversion of testosterone to dihydrotestosterone (extract added)

5알파-리덕타아제 활성억제력은 80% 이상의 결과가 있어야 효과가 있는 것으로 판단한다.5 alpha-reductase activity inhibitory effect is judged to be effective only when 80% or more result.

상기 5알파-리덕타아제 활성 억제력 실험결과는 하기 표 2-1과 같다.The 5 alpha-reductase activity inhibitory test results are shown in Table 2-1.

[표 2-1]TABLE 2-1

Figure kpo00009
Figure kpo00009

피. 아크네스에 대한 살균력 실험blood. Bactericidal Test on Acnes

상기 실시예 및 비교예에서 제조한 비누 조성물의 피. 아크네스에 대한 항균력을 평가 하기 위하여 패트리디쉬(박테리아 배양용 접시)에 피. 아크네스를 접종한 후 3일간 혐기성 배양조에서 배양하고 피, 아크네의 집락수(N1)를 측정하였으며, 5%의 실시예 및 비교예 비누 수용액을 패트리디쉬 상에 떨어뜨려 3일 이상 혐기성 배양조에서 배양시킨 후 집락수(N2)를 측정하였다. 상기에 의하여 구하여진 집락수를 아래의 방법을 이용하여 피. 아크네스에 대한 살균율을 평가하였다.Blood of the soap composition prepared in the above Examples and Comparative Examples. To evaluate antimicrobial activity against Acnes, bleed into Petri Dish (bacterial dish). After inoculation with Acnes, the cells were incubated in an anaerobic culture tank for 3 days, and the colony number (N 1 ) of blood and acne was measured. Colonies (N 2 ) were measured after incubation in the bath. The number of colonies obtained by the above is avoided using the following method. The sterilization rate for Acnes was evaluated.

Figure kpo00010
Figure kpo00010

피. 아크네스의 살균율은 90% 이상의 결과가 있어야 살균효과가 있는 것으로 판단한다.blood. Acne's sterilization rate should be more than 90% to determine the sterilization effect.

상기 피. 아크네스에 대한 살균력 실험결과는 하기 표 2-2에 나타내었다.Said blood. The bactericidal force test results for Acnes are shown in Table 2-2.

[표 2-2]Table 2-2

Figure kpo00011
Figure kpo00011

상기 표에서 보는 바와 같이, 고삼 추출물올 함유한 비누가 이를 함유하지 않은 것보다 5알파-리덕타아제의 활성을 강력하게 억제하는 것으로 나타났으며, 피. 아크네스에 대한 살균력 또한 탁월한 것으로 나타났다. 또한, 위의 결과에서 보듯이 고삼 추출물 0.005 중량% 미만의 첨가시는 5알파-리덕타아제 활성억제력 및 피. 아크네스에 대한 살균력이 다소 낮은 것으로 나타났으며 10 중량% 초과시는 살균력은 우수하지만 제조상의 어려움이 있었다. 따라서 본 발명에 사용된 비누 내의 고삼 추출물의 함량은 0.005∼10 중량% 범위내에서 5알파-리덕타아제의 활성억제력, 피. 아크네스에 대한 살균력 및 작업성이 매우 우수한 것으로 나타났다.As shown in the table, it was found that soaps containing Gosam extract all inhibited the activity of 5-alpha-reductase more strongly than those without it. The bactericidal activity against Acnes was also shown to be excellent. In addition, 5 alpha-reductase activity inhibitory power and blood when the ginseng extract less than 0.005% by weight as shown in the above results. The bactericidal power against Acnes was found to be somewhat low, and when it exceeds 10% by weight, the bactericidal power was excellent, but there were manufacturing difficulties. Therefore, the content of ginseng extract in the soap used in the present invention is within the range of 0.005 to 10% by weight of 5 alpha-reductase activity inhibitory activity, p. The bactericidal power and workability for Acnes were found to be very good.

[실시예 3 : 고삼 추출물 함유 크림 조성물의 제조 및 효능시험]Example 3: Preparation and efficacy test of ginseng extract-containing cream composition

크림 베이스인 유성성분, 수성성분, 계면활성제 등의 조합물과 고삼 추출물을 혼합기에서 잘 유화시키고 탈기, 여과, 냉각하여 크림 조성물을 제조하였으며, 그 이외의 첨가제인 방부제, 킬레이트제, 향료 및 색소 등을 첨가할 수 있으며, 적은 양의 유성 성분이 존재하도록 처방은 수중유형(O/W)으로 제조하였다. 상기의 고삼 추출물은 폼 클렌싱, 로숀, 에센스 등의 기초 화장품에 편리하게 첨가하여 여드름의 예방 및 치료제로서 사용할 수 있다.A cream composition was prepared by emulsifying a combination of a creamy base oil component, an aqueous component, a surfactant, and a ginseng extract in a mixer, degassing, filtration and cooling, and other additives such as preservatives, chelating agents, fragrances, and pigments. The formulation was prepared in oil-in-water (O / W) so that a small amount of oily component could be added. The ginseng extract of the above can be conveniently added to basic cosmetics such as foam cleansing, lotion, essence and the like and can be used as a preventive and therapeutic agent for acne.

Figure kpo00012
Figure kpo00012

5알파-리덕타아제 활성 억제력 평가실험5-alpha-reductase activity inhibitory evaluation test

상기 실시예 및 비교예에서 제조한 크림 조성물의 5알파-리덕타아제에 대한 활성 억제력을 평가하기 위하여 5%의 실시예 및 비교예 크림수용액을 실험액으로 제조하여 상기에 설명한 방법으로 5알파-리덕타아제 활성 억제력을 평가하였다. 억제율 평가계산방법은 아래와 같다.In order to evaluate the inhibitory activity of 5-alpha-reductase activity of the cream compositions prepared in the above Examples and Comparative Examples, 5% of the Example and Comparative Example cream aqueous solutions were prepared as experimental solutions and the 5-alpha- Inhibition of reductase activity was evaluated. The inhibition rate calculation method is as follows.

억제율(%) = [(A-B)/A] x 100% Inhibition = [(A-B) / A] x 100

A = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 미첨가시)A = conversion of testosterone to dihydrotestosterone (without extract)

B = 테스토스테론에서 다이하이드로테스토스테론으로의 전환율(추출물 첨가시)B = conversion of testosterone to dihydrotestosterone (extract added)

5알파-리덕타아제 활성억제력은 80% 이상의 결과가 있어야 효과가 있는 것으로 판단한다.5 alpha-reductase activity inhibitory effect is judged to be effective only when 80% or more result.

상기 5알파-리덕타아제 활성 억제력 실험결과는 하기표 3-1과 같다.The 5 alpha-reductase activity inhibitory test results are shown in Table 3-1.

[표 3-1]Table 3-1

Figure kpo00013
Figure kpo00013

피. 아크네스에 대한 살균력 실험blood. Bactericidal Test on Acnes

상기 실시예 및 비교예에서 제조한 크림 조성물에 대한 살균력을 확인하기 위하여 피. 아크네스를 패트리디쉬(박테리아 배양용 접시)에 접종한 후 3일간 혐기성 배양조에서 배양하고 피, 아크네스의 집락수(N1)를 측정하였으며, 5%의 실시예 및 비교예 크림 수용액올 패트리디쉬 상에 떨어뜨려 3일 이상 혐기성 배양조에서 배양시킨 후 집락수(N2)를 측정하였다. 상기에 의하여 구하여진 집락수를 아래의 방법을 이용하여 피. 아크네스에 대한 살균율을 평가하였다.P. In order to check the bactericidal power of the cream compositions prepared in Examples and Comparative Examples. Acnes was inoculated in a petri dish (bacterial dish), and then cultured in an anaerobic culture tank for 3 days, and the number of colonies (N 1 ) of blood and acnes was measured. Colonies (N 2 ) were measured after incubation in an anaerobic culture vessel for 3 days or more on a dish. The number of colonies obtained by the above is avoided using the following method. The sterilization rate for Acnes was evaluated.

Figure kpo00014
Figure kpo00014

피. 아크네스의 살균율은 90% 이상의 결과가 있어여 살균효과가 있는 것으로 판단한다.blood. Acne's sterilization rate is more than 90% results are judged to have a sterilization effect.

상기 피. 아크네스에 대한 살균력 실험결과는 하기 표 3-2에 나타내었다.Said blood. The bactericidal force test results for Acnes are shown in Table 3-2 below.

[표 3-2]Table 3-2

Figure kpo00015
Figure kpo00015

상기 표에서 보는 바와 같이 고삼 추출물을 함유한 크림이 이를 함유하지 않은 것보다 5알파-리덕타아제의 활성을 강력하게 억제하는 것으로 나타났으며, 피. 아크네스에 대한 살균력 또한 탁월한 것으로 나타났다. 또한, 위의 결과에서 보듯이 고삼 추출물 0.005 중량% 미만의 첨가시는 5알파-리덕타아제 활성억제력 및 피. 아크네스에 대한 살균력이 다소 낮은 것으로 나타났으며, 10 중량% 초과시는 살균력은 우수하지만 제조상의 어려움이 있었다. 따라서 본 발명에 사용된 크림 내의 고삼 추출물의 함량은 0.005∼10 중량% 범위내에서 5알파-리덕타아제의 활성억제력, 피. 아크네스에 대한 살균력 및 작업성이 매우 우수한 것으로 나타났다.As shown in the table, the cream containing the ginseng extract was found to strongly inhibit the activity of 5 alpha-reductase than that containing no ginseng extract. The bactericidal activity against Acnes was also shown to be excellent. In addition, 5 alpha-reductase activity inhibitory power and blood when the ginseng extract less than 0.005% by weight as shown in the above results. The bactericidal power for Acnes was found to be somewhat low, and when it exceeds 10% by weight, the bactericidal power was excellent, but there were manufacturing difficulties. Therefore, the content of ginseng extract in the cream used in the present invention is within the range of 0.005 to 10% by weight of 5 alpha-reductase activity inhibitory activity, p. The bactericidal power and workability for Acnes were found to be very good.

따라서 본 발명에 따라 고삼 추출물 0.005∼10 중량%를 함유하는 세안제, 비누 및 크림은 5알파-리덕타아제의 활성억제력이 뛰어나고 피, 아크네스에 우수한 항균효과가 있으며, 특히 5알파-리덕타아제 및 피. 아크네스의 두가지 인자로 인하여 발병하는 대표적 질환인 여드름의 예방 및 치료 효과도 뛰어난 것으로 평가된다.Therefore, according to the present invention, the cleanser, soap and cream containing 0.005 to 10% by weight of ginseng extract have an excellent inhibitory activity of 5 alpha-reductase and have an excellent antibacterial effect on blood and acnes, especially 5 alpha-reductase. And blood. The two factors of Acnes are considered to be effective in preventing and treating acne, a representative disease that occurs.

Claims (6)

고삼추출물의 건조분말을 0.005 내지 10 중량% 함유함을 특징으로하는 피지 생성 억제작용을 갖는 액상, 크림상, 페이스트상 또는 고체상 조성물.A liquid, cream, paste or solid composition having a sebum production inhibitory activity, characterized by containing 0.005 to 10% by weight of dry powder of high ginseng extract. 제 1항에 있어서, 고삼추출물의 건조분말중, 5α-리덕타아제의 활성을 억제하는 유효성분으로 마트린, 알로마트린, 옥시마트린, 소포라놀 등의 알칼로이드류를 0.05내지 12.9중량% 함유함을 특징으로 하는 조성물.The dry powder of high ginseng extract contains 0.05 to 12.9% by weight of alkaloids such as matrin, allomatrine, oxymatrine, and sophoranol as an active ingredient that inhibits the activity of 5α-reductase. Composition characterized in that. 제 1항에 있어서, 추출용매로서 정제수, 메탄올, 에탄올, 프로판올, 부탄올, 글리세롤, 프로필렌그리콜, 1,3-부틸렌글리콜, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 디에틸에테르 및 디클로로메탄 중에서 선택된 하나 또는 두종류 이상의 혼합 용매를 이용하여 고삼 뿌리를 상온에서 냉침한 후 용매를 증발 또는 동결 건조하여 얻은 추출물임을 특징으로 하는 조성물.The method of claim 1, wherein the extractant is purified water, methanol, ethanol, propanol, butanol, glycerol, propylene glycol, 1,3-butylene glycol, methyl acetate, ethyl acetate, benzene, hexane, diethyl ether and dichloromethane. The extract obtained by cooling the ginseng root at room temperature using one or more selected mixed solvents at room temperature, followed by evaporation or lyophilization of the solvent. 제 1항, 2항 및 3항중 어느 하나에 있어서, 조성물이 여드름 예방 또는 치료제인 조성물.The composition according to any one of claims 1, 2 and 3, wherein the composition is an agent for preventing or treating acne. (2차 정정) 제 1항, 2항 및 3항중 어느 하나에 있어서, 조성물이 탈모 또는 지루성 피부염 예방 또는 치료제인 조성물.(Secondary correction) The composition according to any one of items 1, 2 and 3, wherein the composition is an agent for preventing or treating hair loss or seborrheic dermatitis. 제 1항에 있어서, 조성물이 5알파-리덕타아제(5α-Reductase)의 활성억제 작용을 갖는 것을 특징으로하는 조성물.The composition according to claim 1, wherein the composition has an activity inhibiting activity of 5 alpha -Reductase.
KR1019970031533A 1996-07-12 1997-07-08 Composition having antimicrobial activity for propionibacterium acnes and inhibition activity for 5alpha-reductase KR100311199B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR101996028272 1996-07-12
KR19960028272 1996-07-12
KR1019960028272 1996-07-12

Publications (2)

Publication Number Publication Date
KR980008238A KR980008238A (en) 1998-04-30
KR100311199B1 true KR100311199B1 (en) 2001-12-15

Family

ID=19466221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970031533A KR100311199B1 (en) 1996-07-12 1997-07-08 Composition having antimicrobial activity for propionibacterium acnes and inhibition activity for 5alpha-reductase

Country Status (3)

Country Link
JP (1) JPH1067673A (en)
KR (1) KR100311199B1 (en)
CN (1) CN1170606A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990052470A (en) * 1997-12-22 1999-07-05 성재갑 Composition having a cotton solubility effect
KR20010000390A (en) * 2000-09-26 2001-01-05 이영준 Skin Improvement Composition Including Anti-Aging and Anti-Acne with Kimchi Extract
WO2005099653A1 (en) 2004-04-14 2005-10-27 Eun-Joo Lee Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia
WO2008102997A1 (en) * 2007-02-21 2008-08-28 Biospectrum Inc. Compositions for improving skin conditions comprising matrine or its oxidized derivatives
KR100862967B1 (en) * 2008-06-16 2008-10-13 바이오스펙트럼 주식회사 Compositions for Anti-Obesity Comprising Matrine or Its Oxidized Derivatives
KR100879244B1 (en) * 2008-07-28 2009-01-23 바이오스펙트럼 주식회사 Skin Whitening Agents Comprising Matrine or Its Oxidized Derivatives
US8088775B2 (en) 2004-04-14 2012-01-03 Eun-Joo Lee Pharmaceutical composition for treating hair loss
KR101149545B1 (en) 2010-04-23 2012-05-29 강원대학교산학협력단 Composition for treating skin disease
CN108066679A (en) * 2017-05-22 2018-05-25 安徽菩提生物医药科技有限公司 A kind of composition of children's skin bacteria inhibitor and preparation method thereof
KR102322628B1 (en) * 2021-02-26 2021-11-04 이유정 A method for preparing wild ginseng cultured root extract with increased content of specific ginsenosides and cosmetic composition for relieving hair loss symptoms and promoting hair growth using ginsenoside complexes

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100484236B1 (en) * 1997-08-27 2005-09-08 주식회사 엘지생활건강 Hair Growth Promoting Composition
KR100523540B1 (en) * 1997-12-23 2006-01-12 주식회사 엘지생활건강 Composition Inhibiting Activity of 5α-Reductase and Antimicrobial Activity to Propionibacterium Acnes
DE60137978D1 (en) * 2001-09-28 2009-04-23 Lg Household & Health Care Ltd COMPOSITION FOR PROMOTING HAIR GROWTH
KR100441726B1 (en) * 2001-12-21 2004-07-27 주식회사 태평양 Cosmetic composition for trichogenousness containing Mantidid ootheca extract
CN100581532C (en) * 2004-03-16 2010-01-20 Lg生活健康株式会社 Hair growth agent composition
CN100346791C (en) * 2004-07-08 2007-11-07 中国药科大学 Controlled and released preparation of kurarinone detained in stomach
KR100668878B1 (en) * 2005-07-29 2007-01-12 강민용 Hair growth promoting composition, topical dermatologic drugs for promoting hair growth and the method of the hair growth promoting composition, topical dermatologic drugs for promoting hair growth
CN102908479B (en) * 2012-09-01 2014-06-18 韩乃巍 Traditional Chinese medicine for treating lung wind blood heat type acne
CN104666144A (en) * 2013-11-28 2015-06-03 上海家化联合股份有限公司 5alpha-reductase inhibitor and application thereof
CN105362143A (en) * 2015-11-26 2016-03-02 珠海蕾特恩国际贸易有限公司 Acne-removing essence and preparation method thereof
CN105300997B (en) * 2015-11-30 2016-08-31 贵州远程制药有限责任公司 A kind of detection method of the pharmaceutical preparation treating gynecological inflammation
CN110591842A (en) * 2019-09-30 2019-12-20 广州香枝化妆品有限公司 Plant handmade soap capable of removing mites and acnes and preparation method thereof
CN112057493A (en) * 2020-10-10 2020-12-11 广东丸美生物技术股份有限公司 Sophora flavescens extract and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873372A (en) * 1994-08-31 1996-03-19 Ichimaru Pharcos Co Ltd Antimicrobial agent and preservative and cosmetic containing artocarpin or/and sophoraflavanone g

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873372A (en) * 1994-08-31 1996-03-19 Ichimaru Pharcos Co Ltd Antimicrobial agent and preservative and cosmetic containing artocarpin or/and sophoraflavanone g

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990052470A (en) * 1997-12-22 1999-07-05 성재갑 Composition having a cotton solubility effect
KR20010000390A (en) * 2000-09-26 2001-01-05 이영준 Skin Improvement Composition Including Anti-Aging and Anti-Acne with Kimchi Extract
WO2005099653A1 (en) 2004-04-14 2005-10-27 Eun-Joo Lee Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia
US8088775B2 (en) 2004-04-14 2012-01-03 Eun-Joo Lee Pharmaceutical composition for treating hair loss
WO2008102997A1 (en) * 2007-02-21 2008-08-28 Biospectrum Inc. Compositions for improving skin conditions comprising matrine or its oxidized derivatives
KR100862968B1 (en) * 2007-02-21 2008-10-13 바이오스펙트럼 주식회사 Agents for Improving Wrinkles on Skin Comprising Matrine or Its Oxidized Derivatives
KR100862967B1 (en) * 2008-06-16 2008-10-13 바이오스펙트럼 주식회사 Compositions for Anti-Obesity Comprising Matrine or Its Oxidized Derivatives
KR100879244B1 (en) * 2008-07-28 2009-01-23 바이오스펙트럼 주식회사 Skin Whitening Agents Comprising Matrine or Its Oxidized Derivatives
KR101149545B1 (en) 2010-04-23 2012-05-29 강원대학교산학협력단 Composition for treating skin disease
CN108066679A (en) * 2017-05-22 2018-05-25 安徽菩提生物医药科技有限公司 A kind of composition of children's skin bacteria inhibitor and preparation method thereof
KR102322628B1 (en) * 2021-02-26 2021-11-04 이유정 A method for preparing wild ginseng cultured root extract with increased content of specific ginsenosides and cosmetic composition for relieving hair loss symptoms and promoting hair growth using ginsenoside complexes

Also Published As

Publication number Publication date
CN1170606A (en) 1998-01-21
KR980008238A (en) 1998-04-30
JPH1067673A (en) 1998-03-10

Similar Documents

Publication Publication Date Title
KR100311199B1 (en) Composition having antimicrobial activity for propionibacterium acnes and inhibition activity for 5alpha-reductase
KR20040015917A (en) Topical formulation for prevention and treatment of acne
JP5514739B2 (en) Melanin production inhibitor and topical skin preparation
JP2012001467A (en) Skin external preparation
JP2909825B2 (en) Cosmetics
JPH01311011A (en) Melanization inhibitory drug for external use
KR100523540B1 (en) Composition Inhibiting Activity of 5α-Reductase and Antimicrobial Activity to Propionibacterium Acnes
JP2001342112A (en) Skin care preparation
JPH04338313A (en) Cosmetic
JP4499371B2 (en) Method for producing proanthocyanidins derived from peanuts
JPH1029927A (en) Antiaging agent
KR100860272B1 (en) Method for extraction and purification of effective component from agrimonia pilosa ledeb and crude drug composition containing extract thereof for prevention and treatment of pimple
JP5000964B2 (en) Testosterone 5α-reductase activity inhibitor, androgen receptor antagonist, use thereof, and method for suppressing androgen activity expression
KR100467031B1 (en) Acne prevention and treatment composition
JP3660822B2 (en) Lipase inhibitor
KR20090132322A (en) COMPOSITION HAVING THE ANTIBACTERIAL ACTION TO PROPIONIBACTERIUM ACNES AND THE INHIBITORY ACTION TO 5alpha-REDUCTASE&#39;S ACTIVITY
JP4222973B2 (en) Elastase activity inhibitors and cosmetics
JPS5948808B2 (en) cosmetics
JP3650147B2 (en) Melanin production inhibitor and topical skin preparation
JP3747192B2 (en) Topical skin preparation
KR19990055304A (en) 5α-reductase activity inhibiting composition containing cloves
JP3150841B2 (en) External preparation for skin
KR100491746B1 (en) Composition for prevention and treatment of acne containing P. oleracea extract
KR20120076168A (en) Skin antiaging agent and composition for skin antiaging comprising the same
KR20050079377A (en) Compositions containing the extract of sanguisorba officinalis, which has the inhibitor activity against 5 alpha reductase

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
B601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 19990818

Effective date: 20001130

S901 Examination by remand of revocation
E902 Notification of reason for refusal
GRNO Decision to grant (after opposition)
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130617

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140703

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20150612

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 16

EXPY Expiration of term